Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for primary advanced or recurrent endometrial cancer: a prospective single-arm open-label phase II clinical trial

Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for primary advanced or recurrent endometrial cancer: a prospective single-arm open-label phase II clinical trial

Introduction Recently, immunotherapy has significantly transformed the treatment landscape of endometrial cancer (EC). Results from KEYNOTE-158, RUBY and AtTEnd showed programmed cell death 1 (PD-1) or programmed cell death-ligand 1 inhibitors with promising efficacy in primary advanced or recurrent...

Full description

Saved in:
Bibliographic Details
Main Authors: Bin Liu, Yu Jiang, Yang Sun, Jie Lin, Jian Chen, Lijun Chen, Linlin Yang, Xiaoxiang Chen, Yuzhi Li, Tongyu Liu, Yingtao Lin, Yanhong Zhuo, Chunhua Tu, Jianping Zou
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/5/e094649.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/15/5/e094649.full

Similar Items